Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...

Hims & Hers (NYSE: HIMS) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth of 111% and an increase in 2025 guidance. The results were phenomenal and a ...

First Quarter 2025 Results Key Financial Results Revenue: US$586.0m (up 111% from ...

We recently published a list of Here’s What Fueled These 10 Firms’ Surge. In this article, we are going to take a look at ...

Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.